Amgen's earnings call showcased strong financial performance in 2010 and an optimistic outlook for 2011. The successful launches of Prolia and XGEVA, along with the strategic acquisition of BioVex, indicate potential growth and strengthen the company's position in the oncology market. While increased R&D spending and anticipated healthcare reform costs may impact short-term earnings, the focus on pipeline advancement suggests positive momentum. The stock is likely to experience a positive impact in the short term due to these developments.

[1]